Campbell & CO Investment Adviser LLC Invests $274,000 in Krystal Biotech, Inc. $KRYS

Campbell & CO Investment Adviser LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,991 shares of the company’s stock, valued at approximately $274,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Krystal Biotech by 20.3% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,795 shares of the company’s stock worth $247,000 after purchasing an additional 303 shares in the last quarter. Aviva PLC grew its stake in Krystal Biotech by 9.8% during the 2nd quarter. Aviva PLC now owns 3,575 shares of the company’s stock worth $491,000 after buying an additional 319 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in Krystal Biotech by 6.9% in the second quarter. Los Angeles Capital Management LLC now owns 26,638 shares of the company’s stock valued at $3,662,000 after buying an additional 1,709 shares during the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in Krystal Biotech in the second quarter worth about $401,000. Finally, EFG Asset Management North America Corp. grew its stake in shares of Krystal Biotech by 31.7% during the second quarter. EFG Asset Management North America Corp. now owns 22,878 shares of the company’s stock worth $3,144,000 after acquiring an additional 5,507 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the subject of several research analyst reports. Bank of America increased their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Chardan Capital raised their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Citigroup lifted their price objective on shares of Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Stock Up 1.0%

Shares of KRYS opened at $208.25 on Tuesday. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of 31.22 and a beta of 0.65. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $212.98. The stock’s 50-day moving average price is $181.13 and its 200-day moving average price is $155.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).